anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Composition comprises (in wt.%) an ointment base for external use (40-60), jojoba oil (8-12), kaolin powder (15-30), sericite powder (8-12), a fermented effective microorganism solution (4-8) and Houttuynia cordataextract (2-6). An independent claim is also included for preparing the composition, comprising mixing and stirring the ointment base, jojoba oil, kaolin powder, sericite powder, the fermented effective microorganism solution and Houttuynia cordataextract in the above mentioned amount, fermenting the mixture obtained to produce a first fermented product, mixing and stirring the components of the first fermented product and further mixing the obtained mixture with the first fermented product and aging the obtained mixture. ACTIVITY : Dermatological; Antiinflammatory; Fungicide; Antipruritic; Antiallergic; Vulnerary; Endocrine-Gen. The dermatological activity of the composition was tested on 796 atopic dermatitis patients of 18 years old by administering the composition for 20 days. The results showed that the composition showed a good treating effect on 307 patients, an improvement on 345 patients and no effect on 4 patients. MECHANISM OF ACTION : None given.
The present invention relates to therapeutic ADCs comprising a medicament linked to an anti-cancer antibody or antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody or fragment thereof binds to Trop-2 and the treatment is for treating a Trop-2 positive cancer. Most preferably, the antibody is hRS7. The ADC is administered to a subject having cancer in combination with an ABCG2 inhibitor. The combination therapy may be effective in treating cancers that are resistant to the drug alone and/or to the ADC alone.
MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal. Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
The present disclosure relates generally to derivatives of capsazepine and methods of use thereof In some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases. In some aspects of the present disclosure, the disclosure provides capsazepine derivatives which may be useful in the treatment of cancer. Such cancers that the compounds may be used to treating include but are not limited to breast, cervical, oral, head, neck, or prostate cancer. In some aspects, the compounds may be useful in treating a tumor by direct injection of the compound into the tumor, particularly an oral tumor. In other aspects, the compounds are administered systemically. The compounds of the present disclosure may also be used to treat the pain associated with a tumor for which it is being administered.
In addition to events reported in clinical trials, the following events have been identified during use of alosetron hydrochloride tablets in clinical practice. Because they were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to alosetron hydrochloride tablets.

Gastrointestinal: Impaction, perforation, ulceration, small bowel mesenteric ischemia.

Neurological: Headache.

Skin: Rash.
PROBLEM TO BE SOLVED: To prepare a makeup mask capable of sticking and absorbing a liquid for beautiful skin on the facial skin for a long period and simply performing the sticking operations by preparing a mask body of a water holding web and carrying out specific processing of the mask body. SOLUTION: This makeup mask Z is obtained by using a web of a material having water holding properties and water resistance such as a nonwoven fabric, a paper or a cloth, preparing a mask body 1 having opened parts 11 and 12 corresponding to eyes and a mouth, impregnating the interior of the mask body 1 with a liquid for beautiful skin. A substance capable of radiating far infrared rays when heated to, e.g. about 25 deg.C is preferably stuck to the web of the mask body 1. An electroconductive substance may be applied to a part of a prescribed area at a suitable place in the mask body 1 of the makeup mask Z. For example, silver printing is carried out in parts covering respective openings 11 and 11 for the eyes to provide a part 2 coated with the electroconductive substance. An electrode terminal 35 of an ion introducing device 3 can be connected to the part 2 coated therewith.  That is, the beauty effects can be promoted by radiation of the far infrared rays and the beauty culture can simply be performed by ionic introduction due to the formation of the part 2 coated with the electroconductive substance.
Choroidal neovascularization (CNV) is a serious condition that affects the retina, causing partial or complete blindness in people of different ages. While CNV is a common occurrence in various chorioretinopathies, research on its occurrence in neonates is limited. Human cytomegalovirus (HCMV) is a significant health threat to neonates, with a strong association with retinal angiogenesis. However, there has been limited investigation into HCMV-associated CNV progression. In this article, we extensively studied the expression of different inflammatory cytokines and chemokines during latent HCMV-associated retinal neovascularization. Our research found that HCMV-induced CNV progression was significantly prominent in the presence of AT2R-dependent angiogenesis (p < 0.001), whereas in the absence of HCMV, AT1R-dependent CCL-5-mediated angiogenesis was documented. We also observed significant increases in CCL-19, CCL-21 chemokine responses, followed by CCR-7 chemokine receptor activation (p < 0.001) in HCMV-induced CNV patients compared to HCMV non-induced CNV groups. Furthermore, significant changes in predictive chemokine markers of HCMV-induced CNV were positively correlated with HCMV viremia. These immunological alterations ultimately lead to the switching of NFκB canonical and noncanonical pathways, respectively, in HCMV-induced neonatal CNV and HCMV non-induced CNV. This clinical observation presents a novel hypothesis that ocular HCMV latency poses a noteworthy risk factor for the progression of retinal neovascularization through a distinctive immunological signaling pathway. The current study represents the first of its kind to report on this association, which may have significant implications for the clinical management of patients with ocular HCMV.
The invention discloses a medicament for treating chronic obstructive pulmonary disease (chronic obstructive pulmonary disease for short), which is an over-the-counter medicament for treating respiratory diseases and comprises 11 common Chinese medicaments such as radix astragali preparata, bulbus fritillariae cirrhosae and the like. Processing into capsule, tablet or granule for oral administration. It has mild medicinal properties and no toxic or side effects. Chronic obstructive pulmonary cough with asthma, persistent failure of treatment, turbid phlegm obstructing the lung, and chronic lung deficiency. The medicine can strengthen body resistance and eliminate pathogenic factors, and can treat both principal and secondary aspects of disease. The composition has effects in clearing away heat, eliminating phlegm, relieving chest stuffiness, resolving hard mass, relieving cough, relieving asthma, invigorating lung, invigorating spleen, invigorating kidney, tonifying heart, lowering qi, and regulating absorption during acute stage. The medicine can reduce the frequency and severity of acute attack of chronic obstructive pulmonary disease, control the occurrence of pulmonary hypertension and right heart failure, improve microcirculation, block the development of pulmonary heart disease, prevent the concurrent heart, brain and blood vessel diseases of patients, prevent the trend of lung function decline, improve the life quality of the patients and solve the problem that no specific medicine is available for treating chronic obstructive pulmonary disease at present.
The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
This study was a prospective, double blinded, randomized, multicenter clinical trial. The enrolled posterior semicircular canal benign paroxysmal positional vertigo patients were randomized to one of the three treatment regimens when they are diagnosed with the Dix-Hallpike test. An then the patient was treated with one of the three maneuvers. After 20 minutes, the patient was examined with the Dix-Hallpike test again. The resolution of nystagmus and symptoms were checked. When the nystagmus was sustained, the same treatment was applied once again. And after 20 minutes, the patient was examined with the Dix-Hallpike test too. 1 day after and 7 days after, the patient was re-examined with the Dix-Hallpike test.
A first optical measurement of tissue with a first optical device is initiated. The first optical measurement includes a first shallow optical reading and a first deeper optical reading. A second optical measurement of the tissue with a second optical device spaced is initiated. The second optical device is spaced apart from the first optical device. The second optical measurement includes a second shallow optical reading and a second deeper optical reading. A first difference value between the first shallow optical reading and the first deeper optical reading is determined. A second difference value between the second shallow optical reading and the second deeper optical reading is determined. A large vessel occlusion (LVO) alert is generated when a ratio of the first difference value to the second difference value is larger than a threshold value.
Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
With the emergence of novel variants, Omicron variant caused a different clinical picture than the previous variants and little evidence was reported regarding perioperative outcomes after Omicron variants. The aim of the study was to evaluate the postoperative outcomes of gastrointestinal cancer patients following Omicron variants infection and also to determine the timing of surgery after infection recovery. A total of 124 patients who underwent gastrointestinal cancer surgery with prior SARS-CoV-2 infection between December 2022 and February 2023 were retrospectively reviewed. 174 cases underwent the same operation during December 2018 and February 2019 as control group. SARS-CoV-2-infected patients were further categorized into three groups based on infected time (1-3 weeks; 4-6 weeks; and ≥ 7 weeks). 90.3% of SARS-CoV-2-infected patients had mild symptoms. The COVID-19 vaccination rate was 71.0%, with a full vaccination rate of 48.4%. There were no significant differences in 30-day morbidity and mortality. There was also no significant difference in pulmonary complications, cardiovascular complications, and surgical complications between the three different diagnosis time groups. In conclusion, reducing waiting time for elective surgery was safe for gastrointestinal cancer patients in the context of an increased transmissibility and milder illness severity with Omicron variant.
Long-term maintenance on naltrexone has proven efficacy as a treatment for opiate dependence, but has not been successful clinically because of at least three problems: 1) The transition from opiate to naltrexone precipitates opiate withdrawal unless the patient has been off any opiates for at least seven days; 2) Compliance issues: patients can miss a few naltrexone doses and begin to experience effects from illicit opiates and become re-addicted, at which point naltrexone cannot be restarted without precipitating withdrawal; 3) Naltrexone may produce dysphoria in some patients. The proposed research study will offer opiate dependent patients brief hospitalization for a rapid detoxification from opiate to naltrexone, using buprenorphine, clonidine and clonazepam. If the patient has already undergone detoxification at an outside unit, they will be assessed for opiate dependence using the naloxone challenge. Patients will then be either discharged or entered directly into outpatient treatment where they will be randomly assigned to either the newly developed "Behavioral Naltrexone Therapy" (BNT), a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy or to Compliance Enhancement (CE) therapy, a controlled therapy intended to simulate outpatient psychiatric care. BNT employs behavioral incentives and enlists members of the family and social network to reinforce naltrexone compliance and abstinence. In this current investigation, for both BNT and CE, all patients are maintained on oral naltrexone. Patients are stratified at baseline by presence or absence of lifetime depressive disorder, which the investigators hypothesize will predict dysphoria on naltrexone and non-compliance. Patients are discharged from the hospital, or entered directly, into outpatient treatment at STARS at NYSPI to receive both counseling and Naltrexone, 50 mg per day.
Introduction: There is a growing body of literature supporting the involvement of a health-social approach using complex interventions in enhancing self-care management among community-dwelling older adults. However, there is a paucity of research on how this intervention strategy implements and disseminates in a real community setting. Bridging the gap between research-based evidence and primary health policy and practice is a considerable challenge to researchers, service providers and policymakers. The present pilot study aims to test the feasibility and acceptability of an evidence-based health-management intervention programme to be incorporated into the existing community services provided in the elderly centers. Results of this pilot study will provide important information if the health-social partnership program rooted in the community is acceptable and feasible and factors that may facilitate or hinder implementation when reaching the target group of older adults dwelling in the community. The preliminary outcomes of enhancing self-management and older adults in maximizing their independence in their home environment will also be examined.

Method: The present pilot study adopts an effectiveness-implementation hybrid design and intends to 1) evaluate the effectiveness of a community-based Health-Social Partnership Programme (HSPP) and 2) explore the reach, adoption, implementation, and maintenance of adopting HSPP in the community. The potential subjects will be recruited from the member list of a community centre of the Hong Kong Lutheran social services if they are (1) aged 60 or above, and (2) cognitively competent. Subjects will receive nurse-led case management supported by a social service team. Factors that hinder or facilitate the program delivery will also be examined to determine the implementation and sustained effects of the programme. The measures include the components of RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework. Data will be collected at pre-intervention (T1), post-intervention (T2), and 3 months after intervention (T3).

Discussion: There are conventional randomized controlled trials testing the effects of community-based programs but these trial designs tend to control the contextual factors rather than incorporating the program in the real environment. Positive outcomes may have been produced in these trials but it is uncertain whether the tested intervention program can be rooted in the real life context and sustain in practice. This pilot study chooses to use the hybrid model to not only test the effectiveness but also examine the measures relating to implementation.
FIELD: medicine.SUBSTANCE: invention relates to a star-shaped structure retained in the stomach. The proposed structure includes: a loaded polymer component; the first linker that connects the loaded polymer component to the second polymer component; the second linker that contains at least part of the loaded polymer component or is connected to it, and/or contains at least part of an elastic polymer component or is connected to it. At least one of the loaded polymer component, the second polymer component, the first linker and the second linker contains an elastic polymer component. The loaded polymer component is at least 60% by wt. of the total structure weight. The retained structure is characterized by folding force of at least about 0.2 N. The first linker is capable of decomposing at the first set of physiological conditions; and the second linker is capable of decomposing at the second set of physiological conditions, different from the first set of physiological conditions, and is not essentially capable of decomposing at the first set of conditions. Options of structures retained in the stomach, a system for the delivery of the structure retained in the stomach, and methods for the delivery of the structure retained in the stomach are also proposed.EFFECT: proposed retained structure makes possible the long-term release of active substance via the oral route.74 cl, 52 dwg, 4 tbl, 17 ex
A standardized disk testing procedure2 is recommended for determining susceptibility of aerobic bacteria to clindamycin. A description is contained in the CLEOCIN® Susceptibility Disk (clindamycin) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the CLEOCIN® Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.

CLEOCIN Susceptibility Disks 2 mcg. See package insert for use.

CLEOCIN Susceptibility Powder 20 mg. See package insert for use.

For anaerobic bacteria the minimal inhibitory concentration (MIC) of clindamycin can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
The present invention discloses antidotal coptis decoction and novel application of an active site thereof. The active site is brownish yellow powder which can absorb moisture to some extent and is soluble in hot water and hot diluted alcohol. The reactions of bismuth potassium iodide, potassium mercuric iodide, etc. are positive. The antidotal coptis decoction mainly contains alkaloids, flavonoids and iridoid glycosides, wherein the total content of the alkaloids is from 12.5 to 14.5%, and the total content of the flavonoids is from 31.5 to 32.5%. The HPLC measurement indicates that the content of geniposide is from 7.5 to 8.5%, and the content of baicalin is from 9.5 to 10.5%. The antidotal coptis decoction also contains a certain amount of organic acid sterol, triterpene and other components. The present invention has favorable function of treating ischemic cerebral apoplexy.
Sanitizing composition and its use. The present invention describes sanitizing compositions, preparation methods and their preferred uses that simultaneously allow hands and/or surfaces, objects, footwear, etc. to be sanitized. and monitor the quality of the sanitization process by means of luminescence, immediately, safely, routinely and economically. The compositions comprise a luminescent agent formed by a matrix and a luminescent reagent embedded and/or attached to it, which improves its safety and efficiency.  (Machine-translation by Google Translate, not legally binding)
OBJECTIVES: I. Determine the efficacy of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (DBVE-PC) with filgrastim (G-CSF) followed by consolidative radiotherapy in children with advanced stage Hodgkin's disease. II. Tailor therapy based on rapidity of response in order to minimize cumulative drug dosages. III. Compare the efficacy of dexrazoxane in reducing pulmonary and cardiac toxicity of DBVE-based therapy without compromising response.

OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin and etoposide on days 0 and 1, bleomycin and vincristine on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs. Patients assigned to arm II receive dexrazoxane on days 0, 1, and 7 in addition to therapy as in arm I. Patients who exhibit a complete remission (CR) or provisional CR then receive radiotherapy to the regional field 5 days a week for 2.8 weeks. If the disease is not responsive, 2 more courses of chemotherapy are given. Patients whose disease remains nonresponsive or progresses go off the study. Radiotherapy may follow for others. Patients are followed every 3 months for the first year, every 4 months for the second year, every 6 months for the third year, and then annually thereafter.

PROJECTED ACCRUAL: A total of 277 patients will be accrued for this study within 3 years.